SCHEMBL3835595

SCHEMBL3835595

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(C(CC2CCN(C(=O)OC(C)(C)C)CC2)NC(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
NR3C1 P04150 4/20 0.42
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
HTT P42858 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
UTS2R Q9UKP6 4/20 0.41
CCR8 P51685 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
FPR2 P25090 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3832630 0.88 NPC1 (0.51) KDM4EPKMMAPTTP53HTT
SCHEMBL2474233 0.86 KDM4E (0.46) KDM4EPKMMAPTHTTNPC1
SCHEMBL4391397 0.84 KDM4E (0.47) KDM4EPKMMAPTHTTNPC1
SCHEMBL20601315 0.82 KDM4E (0.58) KDM4EPKMHTTUTS2RMEN1
SCHEMBL20601409 0.82 KDM4E (0.58) KDM4EPKMHTTUTS2RMEN1
SCHEMBL20601318 0.82 KDM4E (0.58) KDM4EPKMHTTUTS2RMEN1
SCHEMBL3835592 0.79 KDM4E (0.45) KDM4EPKMNR3C1MAPTTP53
SCHEMBL20601262 0.79 KDM4E (0.48) KDM4EPKMMAPTTP53HTT
SCHEMBL20601477 0.77 KDM4E (0.58) KDM4EPKMNR3C1MAPTHTT
SCHEMBL20601233 0.75 KDM4E (0.66) KDM4EPKMMAPTHTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 KDM4E 1820/4885PKM 2000/4885NR3C1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.